| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1 |
| Entrez GeneID | 3716 |
| WB Predicted band size | Calculated MW: 133 kDa; Observed MW: 130 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Peptide sequence around aa. 1020~1024 (K-E-Y-Y-T) derived from Human JAK1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于JAK1抗体的3篇代表性文献示例(注：内容为模拟概括，具体文献需根据实际数据库检索确认)：
---
1. **文献名称**：*Selective JAK1 Inhibition in Rheumatoid Arthritis: Mechanistic Insights and Therapeutic Potential*
**作者**：Smith A, et al.
**摘要**：本研究开发了一种高选择性JAK1单克隆抗体，通过阻断JAK1-STAT信号通路抑制促炎细胞因子传导。体外实验显示其可显著降低类风湿关节炎患者滑膜细胞炎症因子表达，小鼠模型验证了其对关节损伤的改善作用，为自身免疫疾病治疗提供新策略。
2. **文献名称**：*Structural Basis of JAK1 Activation by Cytokine Receptors and Targeted Antibody Inhibition*
**作者**：Chen B, et al.
**摘要**：通过冷冻电镜解析JAK1与细胞因子受体复合物的三维结构，揭示其激活机制。基于此设计的人源化抗体可特异性结合JAK1的激酶域，抑制其磷酸化活性。该研究为开发靶向JAK1的精准疗法提供了结构生物学依据。
3. **文献名称**：*Preclinical Evaluation of a Novel Anti-JAK1 Antibody in Inflammatory Bowel Disease Models*
**作者**：Zhang Y, et al.
**摘要**：报道一种新型JAK1中和抗体在结肠炎动物模型中的疗效。该抗体通过阻断IL-6/IFN-γ信号通路，显著减少肠道炎症细胞浸润和黏膜损伤，且相比泛JAK抑制剂具有更好的安全性，提示其治疗炎症性肠病的潜力。
---
建议通过PubMed或Web of Science以“JAK1 antibody”或“JAK1 inhibitor”为关键词检索最新文献，重点关注Nature Immunology、Blood、Journal of Immunology等期刊。实际引用时需核对作者、标题及摘要准确性。
JAK1 (Janus kinase 1) is a tyrosine kinase critical for cytokine signaling, regulating immune responses, inflammation, and cell growth via the JAK-STAT pathway. It associates with cytokine receptors (e.g., IFN, IL-6 family receptors) and activates downstream signaling upon ligand binding. Dysregulated JAK1 is linked to autoimmune diseases (e.g., rheumatoid arthritis, psoriasis), cancers, and immune deficiencies.
JAK1 antibodies are tools used to detect, quantify, or inhibit JAK1 in research and diagnostics. In research, they help study JAK1 expression, phosphorylation, and interactions in disease models. Therapeutic JAK1-blocking antibodies are less common than small-molecule inhibitors (e.g., tofacitinib) but are explored for targeting cytokine receptors upstream of JAK1. Some monoclonal antibodies (e.g., anti-IL-6 receptor) indirectly modulate JAK1 activity by blocking ligand-receptor binding.
Commercial JAK1 antibodies are validated for techniques like Western blot, immunohistochemistry, and flow cytometry. Specificity remains a challenge due to structural homology among JAK family members. Advances in antibody engineering aim to improve selectivity, supporting both mechanistic studies and potential clinical applications in precision medicine.
×
